Toxoplasmic Encephalitis Treatment in Cotrimoxazole-Intolerant Patients

First-Line Alternative Therapy

• The Centers for Disease Control and Prevention recommends pyrimethamine plus clindamycin with leucovorin supplementation as the preferred alternative regimen for patients who cannot tolerate cotrimoxazole, with Grade A-I evidence for treating toxoplasmic encephalitis in sulfa-allergic patients 1, 2, 3
• Pyrimethamine should be administered at 2 mg/kg/day for 3 days, then 1 mg/kg/day, with clindamycin at 5.0-7.5 mg/kg orally 4 times daily, and leucovorin at 10-25 mg/day to prevent bone marrow suppression 4, 5
• The acute therapy phase should continue for 6 weeks, assuming clinical and radiological improvement, with complete blood count monitoring at least weekly during daily pyrimethamine therapy to detect reversible bone marrow suppression 4, 5

Adjunctive Therapy

• The Centers for Disease Control and Prevention suggests adding corticosteroids, such as dexamethasone or prednisone, when CSF protein exceeds 1,000 mg/dL or focal lesions demonstrate substantial mass effect, but discontinue as soon as clinically possible due to immunosuppressive effects 4, 5

Maintenance Therapy

• The Centers for Disease Control and Prevention recommends lifelong suppressive therapy to prevent relapse, continuing the same regimen that achieved clinical response, with pyrimethamine + sulfadiazine providing dual protection against both toxoplasmosis and PCP 6, 7, 8